Introduction
Retroperitoneal sarcomas (RPS) represent a heterogeneous group of rare malignancies with an overall expected incidence of 0.5-1/100 000. Patterns of recurrence vary by histologic subtype, with biologic behavior spanning a broad spectrum from no metastatic potential to a propensity for local recurrence to predominantly distant relapse [1] . Metastatic RPS includes both systemic disease, with lung and liver being the most common sites of distant failure, and multifocal intra-abdominal disease, or sarcomatosis. Despite multimodal treatment, outcomes for metastatic RPS are poor with median overall survival of 16 months [2] and a dismal 5% 5-year survival [3] . Nonetheless, the possibility of long-term survival or even cure remains. Therefore, each case must be considered individually by a multidisciplinary team of sarcoma specialists in order to tailor an appropriate treatment strategy, taking into account a variety of disease-and patient-specific factors.
The existing literature regarding the multidisciplinary management of RPS is limited by the rarity and heterogeneity of this disease, as well as the evolution in histologic classification over time. Investigation of optimal management strategies in a prospective, randomized fashion is constrained by the low incidence of RPS overall, and the applicability of available data to specific histologic subtypes is unclear. The Trans-Atlantic RPS Working Group (TARPSWG) was established in 2013 in an effort to address these challenges, bringing together high-volume sarcoma centers to generate a combined experience of the multidisciplinary management of RPS and to establish consensus regarding various aspects of the approach to this family of diseases. From an original 8 institutions, membership has now expanded across Europe and North America to 35 institutions and consensus documents have been published concerning the management of primary and locally recurrent RPS [4, 5] . The current work addresses the management of metastatic RPS and represents a collation of published literature and expert opinion. The objective of this document is to guide sarcoma specialists, including surgeons, medical and radiation oncologists, pathologists, and radiologists in the diagnosis and treatment of metastatic RPS. Due to the paucity of high-level evidence in this domain, the management of metastatic RPS is heavily nuanced by the experience and expertise of high-volume sarcoma specialists. For this reason, a consensus document reflecting the current practices and recommendations of these opinion leaders and the evidence underpinning them is of great value. Of note, these recommendations were developed with a unanimous consensus. This is reflected by the level of recommendations, which is often high even in the absence of strong data. The importance of an experienced multidisciplinary team for the treatment of metastatic RPS underscores the need for referral of these patients to specialist centers.
Methods
A comprehensive literature search of the PubMed database was carried out encompassing the topics of metastasectomy, ablative therapies, and systemic therapies for soft tissue sarcoma (STS). On the basis of available evidence, a series of best practice recommendations was generated. The first version of the document was drafted and circulated in advance of the 2016 Connective Tissue Oncology Society Annual Meeting in Lisbon, Portugal where it was discussed at the meeting of the TARPSWG. The document was revised in the following months and the second iteration debated at the 2017 Society of Surgical Oncology Annual Meeting in Seattle, Washington. Once informal consensus was achieved, the final version was circulated for approval by all group members. To further validate the document, the 'Appraisal of Guidelines for Research and Evaluation II instrument' (AGREE II) was employed [6, 7] . The overall scores of the different domains after review by four independent experts are shown in the supplementary Table S1 , available at Annals of Oncology online.
The recommendations that follow apply to select subtypes of RPS in the metastatic setting (Table 1) .
Results
Principles of recommended practice from diagnosis to followup are summarized in 43 statements. Each statement has been attributed a level of evidence according to the scale reported in Table 2. 1. Patients with metastatic RPS should be evaluated in specialized sarcoma centers by multidisciplinary teams with expertise and experience in the full range of treatments of this complex and rare family of diseases. If appropriate, care may then be administered at local centers to minimize patient inconvenience. (VA)
Pretreatment assessment
Clinical history and prior treatment. Details regarding the patient's clinical history and treatment(s) of RPS to date should be procured and reviewed, with particular attention to time course and response to therapy.
2. Operative reports from all prior procedures should be obtained and details of resection(s) undertaken to date understood. (VA) 3. If systemic therapy was previously administered, details regarding agent(s), dose (including cumulative dose for anthracyclines), regimen, toxicities, and response to treatment should be ascertained. (VA) 4. If radiotherapy was previously administered, the dose, regimen, volumes, and boundaries of the radiation field should be determined. (VA)
Imaging. Suspected metastases should be characterized using appropriate imaging modalities for the anatomic location(s) in question.
5. Imaging from the time of initial presentation and diagnosis to completion of treatment as well as postoperative baseline, if applicable, should be reviewed. (VB) 6. Computed tomography (CT) is the standard imaging modality for staging of the chest [4, 5, 8] . (IVA) 7. Contrast-enhanced CT of the abdomen and pelvis is the preferred imaging modality for intra-abdominal/retroperitoneal disease [8] . (IVA) 8. If the anatomic relationship of metastases to specific neurovascular structures requires clarification in order to initiate treatment, magnetic resonance imaging (MRI) can be a useful adjunct [9] . (IVB) 9. Suspected liver metastases can be further imaged with triphasic CT, contrast-enhanced MRI, or targeted liver ultrasound if the nature of the liver lesions is in question or if precise determination of burden of disease is necessary for initiation of treatment (e.g. consideration of resection/local therapies) [10] However, biopsy should be considered to rule out alternative pathology (e.g. fibromatosis) when the radiographic appearance is less characteristic. Solitary lesions contralateral to the primary site should be confirmed with tissue diagnosis if feasible as these have a broad differential diagnosis (e.g. lymphoma, germ-cell tumor, schwannoma, paraganglioma, gastrointestinal stromal tumor (GIST), metastasis from another primary). (VB) 15. Biopsies of retroperitoneal and abdominal masses should be obtained under image guidance, ideally without transgressing the peritoneal cavity, and should be carried out by expert radiologists with experience in soft tissue neoplasms. (VA) 16. To ensure adequate tissue sampling, a minimum of four large gauge cores (14G-16G) is advised [15] . There is no role for fine-needle aspiration biopsy in initial diagnostic evaluation for connective tissue neoplasms; however, recurrences of known sarcomas can be accurately detected using fine-needle aspiration. (IVA)
Patient evaluation. 17. Patients should be evaluated with respect to the nature and severity of symptoms as well as performance status in order to guide decisions regarding appropriate treatment modalities and sequencing thereof. This should include a comprehensive assessment of comorbidities and conditions affecting candidacy for multimodal treatment (e.g. geriatric comorbidity indices [16] ), nutritional and functional status, physiologic sequelae of prior treatment (e.g. cardiomyopathy, impaired kidney function), and pain or other disability resulting from metastatic disease. (IVA) 18. Consideration for metastasectomy must take into account the likelihood of achieving a macroscopically complete resection as well as the number and extent of prior operations and complications thereof in order to estimate operative risk and counsel patients regarding anticipated morbidity. (VA)
19. All newly referred patients and patients with a first presentation of metastatic sarcoma should be presented at a multidisciplinary tumor board with sarcoma specialists from surgical, medical, and radiation oncology, radiology, and pathology. Patients relapsing or progressing after treatment of metastases should be re-reviewed at a multidisciplinary tumor board, as should patients exhibiting a favorable response to treatment who might be eligible for resection. A tailored treatment strategy should be formulated on an individual basis taking into consideration disease biology, patient performance status, likelihood of disease control or symptom relief with eligible treatment modalities and risks thereof, as well as patient preference and goals of care. (VA) 20. Patients with suspected synchronous metastases based on equivocal lesions on imaging should not be precluded from appropriate treatment of their primary tumor, but short-term follow-up imaging should be obtained in an attempt to clarify tumor stage. (VA)
21. Early involvement of palliative care specialists is encouraged for symptom management and coordination of services with a view to maintaining active treatment and supportive care within an outpatient environment for as long as possible [17] . (IA) 22. An understanding of patient goals of care should be established before initiation of therapy. (VB)
Treatment
Local therapies. It is widely believed that the best possibility for long-term survival with metastatic RPS involves complete extirpation of disease, with metastasectomy considered the preferred treatment strategy for resectable oligometastatic disease in appropriately selected patients. In recent years, other local therapies such as RFA and stereotactic body radiotherapy have been shown to achieve similar rates of disease control for hepatic and pulmonary metastases and are thus considered acceptable alternatives [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] . Microwave ablation has supplanted RFA as the preferred ablative modality in many centers, based on evidence from other disease sites. These less invasive treatment modalities may offer the benefit of lower complication rates, shortened disruption of systemic treatment, and expanded application to patients deemed unsuitable for major operative intervention. In addition, they can be combined with surgery to achieve complete disease eradication [19, 29, 30] . Although multiple retrospective series demonstrate prolonged survival in patients who have undergone pulmonary or hepatic metastasectomy [18, [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] (Tables 3 and 4) , there is no level 1 evidence to show that any apparent benefit of either metastasectomy or ablative therapies is due to the treatment itself rather than a consistent selection of patients with favorable disease biology. The available literature is further limited by the inclusion of both bone and soft tissue sarcomas, as well as STS of extremity/trunk and retroperitoneal origins, and in the case of hepatic metastasectomy, by the inclusion of metastatic GIST and visceral sarcomas. Prognostic factors consistently shown to be associated with improved overall survival after metastasectomy include a prolonged disease-free interval between treatment of the primary tumor and detection of metastases, and complete resection of all metastatic disease [26, 30-32, 35-41, 46-49] . Resection of synchronous metastases has not been associated with improved survival and thus metastasectomy is typically restricted to the setting of metachronous disease [48, 50] .
23. Following the diagnosis of potentially resectable metastatic disease, a period of observation without any therapy may be considered to establish disease biology, provided the resectability of existing disease is unlikely to be compromised by a planned delay. (VB) 24. Patients being considered for metastasectomy should, in general, meet the following criteria: [51] (IVA)
a. The primary tumor should be completely resected. b. All metastatic disease should be completely resectable or controllable with local ablative therapies, unless palliative resection is being considered for symptom relief or control of progressing foci. c. The patient should have a suitable performance status and the planned procedure should entail acceptable anticipated morbidity for the individual patient. 26. Minimally invasive approaches to metastasectomy may be safely undertaken provided both the surgeon and the treating center have appropriate expertise and experience with these techniques [45, 55, 56] .
(IVB)
Pulmonary metastases: 27. When considering definitive treatment of pulmonary metastases, the possibility of extrapulmonary metastatic disease should be investigated using CT of the abdomen and either bone scan or [18] FDG-PET [57] . (IVA) 28. In selected patients, the presence of concomitant pulmonary and extrapulmonary metastases is not an absolute contraindication to curative treatment, and occasionally prolonged survival can be achieved with complete extirpation of multiorgan disease [33] . (IVB) 29. Lung function should be optimized in advance of pulmonary metastasectomy. Patients should have preoperative pulmonary function tests before planned extensive resection [58] and should achieve complete smoking cessation at least 3 weeks in advance of pulmonary metastasectomy [42] . (IVA) 
30.
Patients with compromised pulmonary function may be candidates for local ablative therapies as these result in less tissue destruction than resection [18, 19, 21, 22, 24, 28] 
. (IVB)
Hepatic metastases: 31. For patients with large-volume liver metastatic disease and limited extrahepatic disease, liver-directed therapies such as transarterial embolization and transarterial chemoembolization may be considered. The evidence for these techniques in metastatic sarcoma is limited [59, 60] , but their documented efficacy in other malignancies has prompted some centers to extrapolate their use to this setting. (IVC) Intra-abdominal metastases: 32. The role of surgery for multifocal intra-abdominal metastases is limited to palliative intervention as dictated by symptoms (e.g. intestinal obstruction, pain control). Incomplete resection confers no survival benefit and can lead to significant morbidity [5] . (IVB) 33. The role of hyperthermic intraperitoneal chemotherapy in sarcomatosis has been investigated, with no evidence of benefit [2] [61] [62] [63] [64] [65] [66] [67] 
. (IIIB)
Recurrent metastases: 34. Surveillance with imaging every 3-6 months is warranted after resection of metastatic disease, as many patients will develop recurrent metastases and some will be candidates for further local or systemic treatment [68] [69] [70] . (IVA) 35. Local ablative therapies should be considered in the treatment of recurrent metastatic disease, taking into account the likelihood of disease control and the anticipated morbidity of these modalities compared with repeat resection. (VB) 36. Repeated metastasectomy for recurrent metastatic disease may be appropriate in patients with evidence of favorable tumor biology (Figure 1 ). High-grade histology, high tumor volume, and short disease-free interval (i.e. <1 year) are associated with poor outcomes after re-resection and should discourage further surgery [31, 36] .
(IVB)
Palliation: 37. Radiotherapy can be used for palliation of symptoms, in particular for pain, dyspnea due to postobstructive atelectasis or pneumonia, and symptoms of spinal compression. (VA) Systemic therapy. Systemic therapy is the preferred first-line approach in patients presenting with synchronous primary and metastatic disease or when complete extirpation of metastatic disease is not possible with surgery or other local techniques [71] [72] [73] . In the event of a favorable response to systemic therapy, defined as either clear regression or stable disease over 6 months, these patients may eventually be considered for resection (Figure 2 ). First-line systemic therapy may also be considered in patients with resectable metastatic disease in order to observe disease biology and determine appropriateness of aggressive local therapy. In the setting of clearly unresectable metastatic disease, the goal of systemic treatment should be maximal prolongation of an acceptable quality of life, balancing the potential benefits of systemic treatment against expected toxicity.
Although the evidence for individual histologic subtypes is limited, a number of prospective, randomized trials are available to guide treatment [74] (Table 5 ). Additional potential therapeutic agents are currently under investigation in pre-clinical and early clinical trials. The following recommendations are based on currently approved therapies for metastatic sarcoma, often guided by histologies and molecular alterations.
38. For patients with indolent or limited disease, an active surveillance policy can be adopted. (VB) 39. Given the poor outcomes and limited options available to patients with metastatic RPS, inclusion in clinical trials is encouraged. Referral to appropriate academic centers for this purpose is recommended. (VA) 40. For first-line systemic treatment in the palliative setting, an anthracycline-based regimen (doxorubicin or epirubicin) either alone or in combination is recommended [75] [76] [77] [78] [79] . (IA) The combination of doxorubicin and olaratumab was shown to be superior in a randomized phase II trial and should be considered for patients with doxorubicin-sensitive histologies [80] . (IIB) 41. If the goal of treatment is tumor downsizing, either for symptomatic relief or possible resection, a combination of doxorubicin with other agents, including high-dose ifosfamide or dacarbazine (DTIC), can be considered [75, 76, 81] . (IA) The combination of doxorubicin and DTIC is preferred in leiomyosarcoma (LMS) and SFT, as ifosfamide may have limited activity in these subtypes [82, 83] . (VA) 42. A multicenter trial randomizing patients with metastatic STS to receive either doxorubicin or gemcitabine/docetaxel in the first-line setting has reported equivalent efficacy but more toxicity with the combination [79] . (IA) Figure 1 . A 59 year-old patient presented with a recurrent multifocal grade 3 dedifferentiated liposarcoma originating from the left retroperitoneum (B). The primary tumor (A) had been resected 6 months prior in a peripheral hospital with microscopically positive margins. At recurrence (B), the patient presented with ipsilateral retroperitoneal nodules (arrows), the largest in the iliac muscle, and limited intraperitoneal nodules (maximum diameter 3cm). She was treated with epirubicine + ifosfamide (5 cycles) with major response (C) at all tumor sites. She then underwent complete surgical resection of multiple peritoneal nodules, en bloc with a 20cm tract of small bowel, and the left retroperitoneal masses. After surgery, two additional cycles of epirubicine and ifosfamide were administered. Twenty months later the patient was diagnosed with a second intraperitoneal recurrence (D). She was treated with 6 cycles of high-dose ifosfamide with dimensional response and then with surgery (D). The single abdominal nodule was resected en bloc with a small bowel loop and a small wedge of stomach. One year later (E) she developed a third recurrence on the stomach that was treated with surgery (partial gastrectomy). Four months later the patient developed a pelvic recurrence that was treated with high-dose ifosfamide for 2 cycles with progression (F, upper figure), then with Trabectedin for 6 cycles with dimensional response (F, lower figure) and then with surgery (excision of the pevic mass en bloc with sigmoid colon, uterus and adnexa). The patient died two years later due to other causes. Arrows, tumor; Dotted line, pre/post-operative imaging; Continuous line, oncological event.
43. There is no clear agent of choice for second-, third-and higher-line treatment, or in the event that anthracycline-based therapy is contraindicated, but the following agents can be considered based on histologic subtype: a. Single-agent ifosfamide can be used for selected subtypes [84] . An infusional schedule of ifosfamide (1 g/m 2 for 14 days followed by 14 days off) may be particularly effective for dedifferentiated liposarcoma (LPS), synovial sarcoma, and malignant peripheral nerve sheath tumor [85] . For synovial sarcoma in particular, high-dose (>10 g/m 2 ) ifosfamide can be effective [86] . (IB) b. Trabectedin can be considered in sensitive histologies, such as LMS and LPS [87, 88] . (IB) c. Eribulin has been shown to confer a survival advantage over treatment with DTIC in advanced pre-treated liposarcoma [89] . (IB) d. For non-LPS, pazopanib can be considered based on the results of a randomized placebo-controlled trial in pre-treated STS [90] . (IB) e. Gemcitabine can be used alone or in combination with docetaxel or DTIC for all subtypes, but especially LMS and undifferentiated pleomorphic sarcoma [79, [91] [92] [93] [94] . (IB) f. DTIC can be used alone or in combination with anthracyclines for LMS and SFT [72, 92, 95] . (IB) g. Antiangiogenics, such as sunitinib, pazopanib, or temozolomide, can be considered for SFT [95] . (IVB) h. Sirolimus and other mTOR inhibitors can be considered in PEComa [96] . (VB) i. Crizotinib and other ALK inhibitors can be considered for inflammatory myofibroblastic tumor, although they are not yet approved for this application [97] . (VB) Figure 2 . A 66 year-old patient presented with a primary localized 10cm grade 2 leiomyosarcoma of the left retroperitoneum and was scheduled for surgery. Preoperative triphasic CT scan (A) performed one month after initial imaging revealed two synchronous pulmonary metastases (12mm in the left lower lobe and 4mm in the left upper lobe, arrows) and progression of the abdominal mass (10cm to 12cm, T). The patient was treated with upfront Adriamycin þ Dacarbazine (DTIC). After two courses the abdominal mass and major lung nodule were stable while the minor lung nodule showed mild progression (4mm to 6mm). The chemotherapy regimen was altered to Gemcitabine 900 mg/m 2 þ DTIC 750 mg/m 2 and after 5 courses the CT scan (B) showed partial response of the lung nodules (12mm to 8mm, 6mm to 3mm, arrows) and stable disease of the primary tumor. The patient then underwent resection of the primary tumor en bloc with the pancreatic tail, spleen, duodenojejunal flexure and part of the portal vein. Two months after surgery the CT scan (C) showed dimensional and numerical progression of the lung nodules and appearance of bilateral liver metastases. Gemcitabine þ Vinorelbine were started with major response in the lungs and partial response in the liver. Eighteen months after the first course of Gemcitabine (D) the lung disease burden was limited and, due to the progression of a single liver nodule, the patient was treated with transarterial chemoembolization with Adriamycin. Twenty-seven months after disease onset the patient is alive with limited disease in the lungs and stable liver metastases.
Conclusions
The probability of cure in the context of metastatic RPS is low, but long-term survival has been achieved with metastasectomy in carefully selected patients, often as part of a multimodal treatment strategy. The literature surrounding the management of metastatic RPS is limited in multiple respects. Although level 1 evidence exists for the selection of systemic therapies, and does suggest a limited survival benefit, these trials include sarcomas arising from a variety of primary sites as well as multiple histologic subtypes with widely variable tumor biology. The data in support of metastasectomy consist largely of retrospective, single-institution case series with relatively small numbers, and these are similarly limited in their generalizability due to inclusion of multiple histologic subtypes and anatomic sites of origin. Published reports for local therapies such as RFA and stereotactic body radiotherapy in the treatment of oligometastatic disease demonstrate good efficacy; however, literature with respect to Survival benefit with eribulin in LPS and LMS RPS is scant and further work is needed to clarify the role of nonsurgical local management. This consensus document is intended to add to the limited available literature the practical expertise of multiple highvolume sarcoma centers and to serve as a tool for decision making in the complex, multidisciplinary management of this family of diseases. Implementation of the recommendations contained herein may be limited by lack of approval or availability of the described treatment modalities in certain jurisdictions or centers. Referral to specialist centers is strongly encouraged to ensure that patients have access to the full armamentarium of therapeutic options, including experimental therapies.
A prospective registry has been established to improve the quality of evidence going forward and to afford a better understanding of metastatic RPS in order to optimize the complementarity of survival and quality of life. This registry may also allow for investigation of adherence to the recommendations put forth here.
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